Recombinant Human Hyaluronidase is named as a drug or biological intervention in 2 clinical trials in our UK, USA and China trial registers, 1 of which is recruiting. Lead sponsors include AstraZeneca (1) and Shanghai Henlius Biotech (1). Registered phase: Phase 1. Conditions studied include Advanced Solid Tumors; Healthy Adult Male.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07161414 | A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ClinicalTrials.gov ↗) Advanced Solid Tumors |
Phase 1 | Recruiting |
| NCT07484893 | A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects (ClinicalTrials.gov ↗) Healthy Adult Male |
Phase 1 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Advanced Solid Tumors | 1 |
| Healthy Adult Male | 1 |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 1 |
| Shanghai Henlius Biotech | 1 |
| Register | Recombinant Human Hyaluronidase trials |
|---|---|
| Clinical trials in UK | 1 |
| Clinical trials in USA | 1 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Recombinant Human Hyaluronidase works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Recombinant Human Hyaluronidase (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.